Septerna
Market cap $1.90B 47.5M shares (10-Q, Nov 4, 2026) × $40.02 close Nov 17, 2026
Most recent annual filing: 2026-03-09
- BIOSECURE Act restricted supplier listDec 18, 2026BIOSECURE Act restricted supplier list, Dec 18, 2026, routine
- SEP-479 Ph1 topline1Q 2027SEP-479 Ph1 topline, 1Q 2027, thesis-defining
- SEP-204 Ph1 start1Q 2027SEP-204 Ph1 start, 1Q 2027, notable
- Immunovant IMVT-1402 pivotal readout2027Immunovant IMVT-1402 pivotal readout, 2027, notable
- BridgeBio encaleret PDUFA dateMay 8, 2027BridgeBio encaleret PDUFA date, May 8, 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
SEP-631
SEP-204
Technology platforms
Native Complex Platform · Novo Nordisk
Proprietary GPCR drug discovery platform that replicates the natural structure, function, and dynamics of GPCRs outside of cells at industrial scale. Enables isolation, purification, and reconstitution of full-length GPCR proteins in ternary complexes with ligands and transducer proteins in a lipid bilayer. Supports structure-based drug design of oral small molecule agonists, antagonists, and allosteric modulators across endocrinology, immunology, inflammation, and metabolic diseases. Used both in wholly-owned programs and in collaboration with Novo Nordisk for GLP-1, GIP, and glucagon receptor-targeted metabolic disease programs.
Targets: GLP-1 receptor, GIP receptor, glucagon receptor, MRGPRX2, PTH1R, TSHR, GLP-1R, GIPR, GCGR
Native Complex Platform
Industrialized GPCR drug discovery platform enabling isolation of fully functional GPCR proteins in native lipid bilayer complexes; supports high-resolution structure determination, screening of billions of compounds, and iterative structure-based drug design; focus on difficult-to-drug GPCRs across endocrinology, immunology/inflammation, neurology, women's health, cardiovascular, respiratory, and metabolic diseases
Native Complex Platform · Novo
Proprietary industrial-scale GPCR drug discovery platform that replicates the natural structure, function, and dynamics of GPCRs outside of cells, enabling isolation, purification, and reconstitution of full-length GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer; supports structure-based drug design for agonists, antagonists, and allosteric modulators across endocrinology, immunology, inflammation, and metabolic diseases
Targets: GLP-1 receptor, GIP receptor, glucagon receptor
Discontinued (1)
- SEP-786 — Hypoparathyroidism · Two unanticipated severe Grade 3 events of elevated unconjugated bilirubin in MAD portion; found to be a potent UGT1A1 inhibitor
Capital (as filed)
- Cash
- $167M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $311M Sep 30, 2026
- Long-term investments
- $86.6M Sep 30, 2026
- Operating cash flow
- −$13.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $565M cash, runway mid-2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-10 UPDATE: Septerna (SEPN) - Everyone Sold the Jump 🔒 Paid
- 2026-11-06 Septerna (SEPN) - Scientific Deep Dive for SEP-479, SEP-204 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Septerna, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-11-06 Watch Septerna (SEPN) - Scientific Deep Dive for SEP-479, SEP-204 and Pipeline Products Septerna's EV already prices in SEP-479 working before any human PD data, and both prior oral PTH1R agonists failed in the clinic, making the risk/reward unattractive at current levels.
- 2026-11-10 Watch UPDATE: Septerna (SEPN) - Everyone Sold the Jump Q1 2027 readout remains on schedule but the stock is now ~11% above the probability-weighted fair value and near its 52-week high, with insiders and smart money selling into strength, making the watch stance unchanged.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Our planned use of the net proceeds from the IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the “Securities Act”) on October 25, 2024 has changed due to the discontinuation of the development of our prior lead product candidate, SEP-786, and the selection of SEP-204 as our oral TSHR negative allosteric modulator development candidate in November 2026.”
matched to SEP-204 · trial initiation -
“As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.”
matched to SEP-479 · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (18)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 9, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseSepterna Highlights Business Progress and Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD updateSepterna's Q3 earnings arrive with a double catalyst: SEP-204 formally selected as TSHR development candidate (new preclinical animal data at ATA), and Q3 financials reveal the burn is accelerating — $36.6M R&D in a single quarter — alongside a fresh wave of executive 10b5-1 selling plans from the CEO, CFO, and COO.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Aug 25, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Aug 14, 2026SCHEDULE 13D/A13D amendment
- Aug 10, 20268-KCurrent report: results of operations · EX-99.1
- Aug 10, 202610-QQuarterly report
- Jun 30, 20268-KCurrent report: shareholder vote
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 11, 202610-QQuarterly report
- Apr 30, 2026DEFA14AProxy soliciting material
- Apr 30, 2026DEF 14AProxy statement
- Apr 13, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 10, 2026S-3ASRAutomatic shelf registration
- Mar 9, 20268-KCurrent report: results of operations · EX-99.1
- Mar 9, 202610-KAnnual report
- Mar 2, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Apr 30, 2026ARSAnnual report to shareholders
- Mar 9, 2026S-8Employee plan registration